GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Institutional Ownership

Cantargia AB (FRA:7V3) Institutional Ownership : 4.81% (As of Apr. 14, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cantargia AB's institutional ownership is 4.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cantargia AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cantargia AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Cantargia AB Institutional Ownership Historical Data

The historical data trend for Cantargia AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Institutional Ownership Chart

Cantargia AB Historical Data

The historical data trend for Cantargia AB can be seen below:

2024-05-31 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 6.32 6.40 6.40 6.21 6.20 5.59 5.31 5.62 4.81 4.81

Cantargia AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Institutional Ownership
Comparable Companies
OSTO:INIT OSTO:IVACC OSTO:XBRANE OSTO:LIPUM OSTO:ISOFOL OSTO:ONCO OSTO:IRLAB A OSTO:IMMU OSTO:XINT OSTO:ACE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CANTA:Sweden
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Website
https://www.cantargia.com
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines